OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - NOVO-NORDISK B | Real-time Boerse Frankfurt Warrants 07:55:27 13/06/2024 BST | ||
| 21.06 EUR | +0.19% |
|
| Current month | +8.66% | ||
| 1 month | +14.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 13/06/24 | 21.06 | +0.19% |
| 12/06/24 | 20.95 | -0.10% |
| 11/06/24 | 20.97 | -0.99% |
| 10/06/24 | 21.18 | +0.95% |
| 07/06/24 | 20.98 | +2.19% |
Real-time Boerse Frankfurt Warrants
Last update June 13, 2024 at 07:55 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | CL9B3V |
| ISIN | DE000CL9B3V7 |
| Date issued | 07/04/2020 |
| Strike | 205 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.22 € |
|---|---|
| Lowest since issue | 0.45 € |
| Spread | 0.01 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
989.6
DKK
Average target price
929.5
DKK
Spread / Average Target
-6.08%
- Stock Market
- Certificates
- Certificat